| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical & Dental University, Tokyo 113-8510, Japan [I. I., Z-Q. Y., A. P., J. I.]; Second Department of Pathology, National Defense Medical College, Saitama 359-8513, Japan [H. T.]; Department of Surgery, Surgically Basic Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan [Y. S., M. I.]; and Cancer Genomics Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan [M. O.]
Amplification of chromosomal DNA is thought to be one of the mechanisms that activate cancer-related genes in tumors. In a recent study, we identified high copy-number amplification at 11q21-q23 in cell lines derived from esophageal squamous cell carcinomas (ESCs) using comparative genomic hybridization. Because 11q21-q23 amplification has been reported in tumors of various other types as well, gene(s) associated with tumor progression may lie within this chromosomal region. To identify the most likely target(s) for amplification at 11q21-q23, we determined the extent of the amplicon by fluorescence in situ hybridization and then analyzed ESC cell lines for expression levels of 11 known genes and one uncharacterized transcript present within the 1.8-Mb commonly amplified region. Only cIAP1, a member of the IAP (antiapoptotic) gene family, was consistently overexpressed in cell lines that showed amplification. Additionally, the cIAP1 protein was overexpressed in the primary tumors from which those cell lines had been established. The ESC cell lines with cIAP1 amplification were resistant to apoptosis induced by chemotherapeutic reagents. An increase in cIAP1 copy number was also detected in 4 of 42 (9.5%) primary ESC tumors that were not related to the cell lines examined. Because inhibition of apoptosis seems to be an important feature of carcinogenesis, cIAP1 is likely to be a target for 11q21–23 amplification and may be involved in the progression of ESC, as well as other malignancies.
This article has been cited by other articles:
|
|
 |
|
  R. A. Csomos, G. F. Brady, and C. S. Duckett Enhanced Cytoprotective Effects of the Inhibitor of Apoptosis Protein Cellular IAP1 through Stabilization with TRAF2 J. Biol. Chem., July 31, 2009; 284(31): 20531 - 20539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Ma, W.-W. Cai, L. Zender, T. Dayaram, J. Shen, A. J. Herron, S. W. Lowe, T.-K. Man, C. C. Lau, and L. A. Donehower MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression Cancer Res., March 15, 2009; 69(6): 2559 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yokoyama, H. Osada, H. Murakami, Y. Tatematsu, T. Taniguchi, Y. Kondo, Y. Yatabe, Y. Hasegawa, K. Shimokata, Y. Horio, et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation Carcinogenesis, November 1, 2008; 29(11): 2139 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sekine, K. Takubo, R. Kikuchi, M. Nishimoto, M. Kitagawa, F. Abe, K. Nishikawa, T. Tsuruo, and M. Naito Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation J. Biol. Chem., April 4, 2008; 283(14): 8961 - 8968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Gibcus, L. Menkema, M. F. Mastik, M. A. Hermsen, G. H. de Bock, M.-L. F. van Velthuysen, R. P. Takes, K. Kok, C. A. Alvarez Marcos, B. F.A.M. van der Laan, et al. Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6257 - 6266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vucic and W. J. Fairbrother The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer Clin. Cancer Res., October 15, 2007; 13(20): 5995 - 6000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Esposito, J. Kleeff, I. Abiatari, X. Shi, N. Giese, F. Bergmann, W. Roth, H. Friess, and P. Schirmacher Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer J. Clin. Pathol., August 1, 2007; 60(8): 885 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pan Hippo signaling in organ size control Genes & Dev., April 15, 2007; 21(8): 886 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Overholtzer, J. Zhang, G. A. Smolen, B. Muir, W. Li, D. C. Sgroi, C.-X. Deng, J. S. Brugge, and D. A. Haber Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon PNAS, August 15, 2006; 103(33): 12405 - 12410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Volp, M-L Brezniceanu, S Bosser, T Brabletz, T Kirchner, D Gottel, S Joos, and M Zornig Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas Gut, February 1, 2006; 55(2): 234 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mishra, J. P. Mishra, K. Gee, D. C. McManus, E. C. LaCasse, and A. Kumar Distinct Role of Calmodulin and Calmodulin-dependent Protein Kinase-II in Lipopolysaccharide and Tumor Necrosis Factor-{alpha}-mediated Suppression of Apoptosis and Antiapoptotic c-IAP2 Gene Expression in Human Monocytic Cells J. Biol. Chem., November 11, 2005; 280(45): 37536 - 37546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Conze, L. Albert, D. A. Ferrick, D. V. Goeddel, W.-C. Yeh, T. Mak, and J. D. Ashwell Posttranscriptional Downregulation of c-IAP2 by the Ubiquitin Protein Ligase c-IAP1 In Vivo Mol. Cell. Biol., April 15, 2005; 25(8): 3348 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, R. M. Thomas, H. Suzuki, J. K. De Brabander, X. Wang, and P. G. Harran A Small Molecule Smac Mimic Potentiates TRAIL- and TNF{alpha}-Mediated Cell Death Science, September 3, 2004; 305(5689): 1471 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sonoda, I. Imoto, J. Inoue, T. Shibata, Y. Shimada, K. Chin, M. Imamura, T. Amagasa, J. W. Gray, S. Hirohashi, et al. Frequent Silencing of Low Density Lipoprotein Receptor-Related Protein 1B (LRP1B) Expression by Genetic and Epigenetic Mechanisms in Esophageal Squamous Cell Carcinoma Cancer Res., June 1, 2004; 64(11): 3741 - 3747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yokoi, K. Yasui, T. Iizasa, I. Imoto, T. Fujisawa, and J. Inazawa TERC Identified as a Probable Target within the 3q26 Amplicon That Is Detected Frequently in Non-Small Cell Lung Cancers Clin. Cancer Res., October 15, 2003; 9(13): 4705 - 4713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hong, L. Lei, and R. Glas Tumors Acquire Inhibitor of Apoptosis Protein (IAP)-mediated Apoptosis Resistance through Altered Specificity of Cytosolic Proteolysis J. Exp. Med., June 16, 2003; 197(12): 1731 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, T. Yokoyama, S. Nozawa, J. Inazawa, and I. Imoto Association of 17q21-q24 Gain in Ovarian Clear Cell Adenocarcinomas with Poor Prognosis and Identification of PPM1D and APPBP2 as Likely Amplification Targets Clin. Cancer Res., June 1, 2003; 9(6): 1995 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saito-Ohara, I. Imoto, J. Inoue, H. Hosoi, A. Nakagawara, T. Sugimoto, and J. Inazawa PPM1D Is a Potential Target for 17q Gain in Neuroblastoma Cancer Res., April 15, 2003; 63(8): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dai, W.-G. Zhu, C. D. Morrison, R. M. Brena, D. J. Smiraglia, A. Raval, Y.-Z. Wu, L. J. Rush, P. Ross, J. R. Molina, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes Hum. Mol. Genet., April 1, 2003; 12(7): 791 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jin, M. Kalkum, M. Overholtzer, A. Stoffel, B. T. Chait, and A. J. Levine CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals Genes & Dev., February 1, 2003; 17(3): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Imoto, H. Tsuda, A. Hirasawa, M. Miura, M. Sakamoto, S. Hirohashi, and J. Inazawa Expression of cIAP1, a Target for 11q22 Amplification, Correlates with Resistance of Cervical Cancers to Radiotherapy Cancer Res., September 1, 2002; 62(17): 4860 - 4866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yokoi, K. Yasui, F. Saito-Ohara, K. Koshikawa, T. Iizasa, T. Fujisawa, T. Terasaki, A. Horii, T. Takahashi, S. Hirohashi, et al. A Novel Target Gene, SKP2, within the 5p13 Amplicon That Is Frequently Detected in Small Cell Lung Cancers Am. J. Pathol., July 1, 2002; 161(1): 207 - 216. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
